Study of Microwave Ablation with Lenvatinib for Recurrent Liver Cancer A Randomized Trial for Adults Aged 18 to 75 with Hepatocellular Carcinoma

What this Trial Is About

Researchers are evaluating the safety and effectiveness of combining microwave ablation with lenvatinib for treating recurrent hepatocellular carcinoma HCC, a common type of liver cancer. Microwave ablation is already used as a main treatment for early-stage recurrent HCC, while lenvatinib has shown similar overall survival results compared to sorafenib in advanced liver cancer. This trial aims to explore the benefits and risks of using both treatments together for recurrent HCC, which has not been studied before. Participants will be randomly assigned to one of two groups one group will receive microwave ablation alone, and the other will receive microwave ablation combined with lenvatinib. Lenvatinib doses depend on body weight, with 80 mg for participants weighing 60 kg or less and 120 mg for those weighing more than 60 kg. The study is prospective, randomized, and conducted at multiple centers to assess these treatment approaches. During the study, researchers will monitor participants for tumor-free survival and overall survival rates at 36 months. They will also track adverse events over 24 months and complication rates over 36 months. Participants will undergo regular assessments including laboratory tests and clinical evaluations to ensure safety and measure treatment effects. The total study duration involves follow-up visits up to three years to gather comprehensive outcome data.

Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma